HC Wainwright Issues Pessimistic Forecast for AVTX Earnings

Avalo Therapeutics, Inc. (NASDAQ:AVTX) – Analysts at HC Wainwright decreased their FY2025 earnings estimates for shares of Avalo Therapeutics in a research note issued on Monday, November 24th. HC Wainwright analyst M. Kapoor now forecasts that the company will post earnings of ($7.22) per share for the year, down from their previous forecast of ($6.82). HC Wainwright currently has a “Buy” rating and a $25.00 price target on the stock. The consensus estimate for Avalo Therapeutics’ current full-year earnings is ($19.07) per share. HC Wainwright also issued estimates for Avalo Therapeutics’ Q4 2025 earnings at ($1.74) EPS, Q1 2026 earnings at ($1.76) EPS, Q2 2026 earnings at ($1.61) EPS, Q3 2026 earnings at ($1.63) EPS, Q4 2026 earnings at ($1.65) EPS and FY2026 earnings at ($6.64) EPS.

Several other equities analysts also recently issued reports on the stock. Cantor Fitzgerald started coverage on shares of Avalo Therapeutics in a report on Friday, August 15th. They set an “overweight” rating on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Avalo Therapeutics in a report on Tuesday, October 14th. TD Cowen assumed coverage on shares of Avalo Therapeutics in a research note on Friday, September 5th. They set a “buy” rating for the company. BTIG Research reissued a “buy” rating and issued a $40.00 target price on shares of Avalo Therapeutics in a research report on Monday, September 29th. Finally, Cowen started coverage on Avalo Therapeutics in a research note on Friday, September 5th. They issued a “buy” rating for the company. Nine analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $31.67.

Avalo Therapeutics Price Performance

Shares of NASDAQ:AVTX opened at $18.55 on Wednesday. The business’s 50-day moving average is $15.39 and its 200 day moving average is $9.68. Avalo Therapeutics has a 1 year low of $3.39 and a 1 year high of $19.41. The firm has a market capitalization of $336.31 million, a P/E ratio of -3.46 and a beta of 0.94.

Avalo Therapeutics (NASDAQ:AVTX) last released its quarterly earnings results on Thursday, November 6th. The company reported ($2.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.67) by ($0.52).

Institutional Investors Weigh In On Avalo Therapeutics

Several hedge funds have recently bought and sold shares of the stock. BIT Capital GmbH purchased a new position in shares of Avalo Therapeutics during the 3rd quarter valued at approximately $25,000. Quadrature Capital Ltd acquired a new stake in Avalo Therapeutics during the second quarter valued at $55,000. Boothbay Fund Management LLC purchased a new position in Avalo Therapeutics in the second quarter valued at $56,000. ADAR1 Capital Management LLC purchased a new position in Avalo Therapeutics in the first quarter valued at $80,000. Finally, Dimensional Fund Advisors LP acquired a new position in shares of Avalo Therapeutics in the third quarter worth about $143,000. Hedge funds and other institutional investors own 87.06% of the company’s stock.

Avalo Therapeutics Company Profile

Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.